초록 ▼

Parenteral vaccine formulations and adjuvant compositions comprising certain salts as adjuvants are disclosed. Such parenteral vaccine formulations are used for generating an immune response in a subject following administration of the vaccine formulation or the adjuvant composition. Also disclosed

Parenteral vaccine formulations and adjuvant compositions comprising certain salts as adjuvants are disclosed. Such parenteral vaccine formulations are used for generating an immune response in a subject following administration of the vaccine formulation or the adjuvant composition. Also disclosed is the use of these salts as adjuvants in parenteral vaccine formulations and adjuvant compositions, and to vaccine adjuvants comprising such salts.

대표청구항 ▼

The invention claimed is: 1. A parenteral immunogenic composition comprising a liquid solution consisting essentially of (a) at least one immunogenic substance selected from the group consisting of an antigen, an allergen, an allergoid, a peptide, a protein, a hapten, a carbohydrate, a peptide nucl

The invention claimed is: 1. A parenteral immunogenic composition comprising a liquid solution consisting essentially of (a) at least one immunogenic substance selected from the group consisting of an antigen, an allergen, an allergoid, a peptide, a protein, a hapten, a carbohydrate, a peptide nucleic acid (PNA), a ribonucleic acid (RNA), viral material, bacterial material, a deoxyribonucleic acid (DNA), a parasite, a retrovirus, a toxin, and mycoplasma; and (b) magnesium carbonate hydroxide pentahydrate, wherein magnesium carbonate hydroxide pentahydrate is in suspension. 2. A parenteral immunogenic composition according to claim 1, further comprising an additional adjuvant. 3. A parenteral immunogenic composition according to claim 2, wherein the additional adjuvant is selected from the group consisting of a saponin, MF59, Monophosphoryl lipid A (MPL), polylactide co-glycolide (PLG), polylactide co-glycolide acid (PLGA), calcium phosphate, Freund's incomplete adjuvant (IFA), Freund's complete adjuvant, an interleukin, a glucan, cholera holotoxin, a liposome, muramyl dipeptide, muramyl tripeptide, 1,1,dichloro-2,2,bis(p-chlorophenyl)ethylene (DDE), Dehydroepiandrosterone (DHEA), dimyristoylphosphatidylcholine (DMPC), dimyristoylphosphatidyl-glycerol (DMPG), deoxycholic acid/alum complex (DOC/alum complex), phospatidylethanolamine and an aluminum salt. 4. A parenteral immunogenic composition according to claim 1, further comprising a pharmaceutically acceptable excipient or carrier. 5. A parenteral immunogenic composition according to claim 1, further comprising a diluent, a buffer, a suspending agent, a solubilizing agent, a pH-adjusting agent, a dispersing agent, or a colorant. 6. A parenteral immunogenic composition according to claim 1, for intravenous, intramuscular, intraarticular, subcutaneous, intradermal, epicutaneous, or intraperitoneal administration. 7. A parenteral immunogenic composition according to claim 3, wherein the saponin is selected from the group consisting of Quil A and Qs-21. 8. A method for generating an immune response in an individual, comprising administering to the individual the immunogenic composition of claim 1. 9. The immunogenic composition of claim 1, wherein the immunogen is dissolved in the liquid solution. 10. The parenteral immunogenic composition of claim 1, wherein the immunogenic substance is an allergen or allergoid. 11. A parenteral immunogenic composition comprising (a) at least one immunogenic substance selected from the group consisting of an antigen, an allergen, an allergoid, a peptide, a protein, a hapten, a carbohydrate, a peptide nucleic acid (PNA), a ribonucleic acid (RNA), viral material, bacterial material, a deoxyribonucleic acid (DNA), a parasite, a retrovirus, a toxin, and mycoplasma, and (b) magnesium carbonate hydroxide pentahydrate, and the immunogenic composition is a liquid, wherein magnesium carbonate hydroxide pentahydrate is in suspension. 12. A parenteral immunogenic composition according to claim 11, further comprising an additional adjuvant. 13. A parenteral immunogenic composition according to claim 12, wherein the additional adjuvant is selected from the group consisting of a saponin, MF59, Monophosphoryl lipid A (MPL), polylactide co-glycolide (PLG), polylactide co-glycolide acid (PLGA), calcium phosphate, Freund's incomplete adjuvant (IFA), Freund's complete adjuvant, an interleukin, a glucan, cholera holotoxin, a liposome, muramyl dipeptide, muramyl tripeptide, 1,1,dichloro-2,2,bis(p-chlorophenyl)ethylene (DDE), Dehydroepiandrosterone (DHEA), dimyristoylphosphatidylcholine (DMPC), dimyristoylphosphatidyl-glycerol (DMPG), deoxycholic acid/alum complex (DOC/alum complex), phospatidylethanolamine and an aluminum salt. 14. A parenteral immunogenic composition according to claim 11, further comprising a pharmaceutically acceptable excipient or carrier. 15. A parenteral immunogenic composition according to claim 11, further comprising a diluent, a buffer, a suspending agent, a solubilizing agent, a pH-adjusting agent, a dispersing agent, or a colorant. 16. A parenteral immunogenic composition according to claim 11, for intravenous, intramuscular, intraarticular, subcutaneous, intradermal, epicutaneous, or intraperitoneal administration. 17. A parenteral immunogenic composition according to claim 13, wherein the saponin is selected from the group consisting of Quil A and Qs-21. 18. The immunogenic composition of claim 11, wherein the formulation is suitable for parenteral administration. 19. The immunogenic composition of claim 11, wherein the immunogen is dissolved in the liquid solution. 20. The parenteral immunogenic composition of claim 11, wherein the immunogenic substance is an allergen or allergoid.